Clinical trial
The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection
NCT00002298 · ICN Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00002298 |
|---|---|
| Title | The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection |
| Official title | Long-Term Efficacy and Tolerance of Oral Ribavirin Compared to Placebo as a Preventative in Early Stages of Human Immunodeficiency Virus Infection - United States |
| Lead sponsor | ICN Pharmaceuticals, Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Ribavirin |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: